Condition

IgA Nephropathy (IgAN) clinical trials and research

• 17Clinical trials
• 1New in 30 days
• 11Countries

Newest IgA Nephropathy (IgAN) clinical trials

All recruiting trials (17)

• JADE101 in IgA Nephropathy (phase 3, blinded)

  This phase 3 study tests whether JADE101 helps adults with IgA nephropathy more than a placebo.

  Recruiting at 4 sites Phase 3 Jade Biosciences, Inc. · Arvada, Colorado and 3 other locations · NCT07902817

• Personalized IgA Nephropathy treatment guided by Gd-IgA1 monitoring

  This study tests whether regularly checking a biomarker called Gd-IgA1 to guide treatment with Nefecon or telitacicept helps people with IgA nephropathy or related nephritis respond better.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07822100

• Long-term safety and effectiveness of HSK39297 tablets in IgA nephropathy patients who completed prior study

  This phase 2 trial tests whether taking HSK39297 once daily for IgA nephropathy is safe over the long term and helps reduce protein in the urine for patients who completed a previous study and meet criteria.

  Recruiting Phase 2 Haisco Pharmaceutical Group Co., Ltd. · Beijing and 1 other locations · NCT07616700

• Everest001: a medicine for certain kidney diseases to see if it helps adults

  This study tests EVER001 in adults with FSGS, MCD, or IgA nephropathy to see if it can help reduce protein in the urine and improve kidney function.

  Recruiting at 2 sites Phase 2 Everest Medicines (China) Co.,Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07614477

• Nefecon as a maintenance therapy to prevent relapse in IgA nephropathy

  This study tests whether continuing Nefecon after initial remission can lower the chance of relapse in adults with IgA nephropathy.

  Recruiting Phase 4 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07604311

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

• Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease

  This Phase 1 study will test a donor-derived CAR‑T therapy that targets CD19 and BCMA to try to reset the immune system in people with refractory B‑cell autoimmune diseases such as SLE, IgA nephropathy, systemic sclerosis, and resistant nephrotic syndrome.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07507201

• HSK39297 tablets for adults with primary IgA nephropathy

  This trial will try HSK39297 tablets versus placebo to lower proteinuria and protect kidney function in adults with primary IgA nephropathy.

  Recruiting at 9 sites Phase 3 Haisco Pharmaceutical Group Co., Ltd. · Huangshan City, Anhui and 8 other locations · NCT07390123

• Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases

  This study will try a single infusion of off‑the‑shelf CAR T cells that target CD19 and BCMA to treat people with B‑cell–mediated autoimmune diseases such as lupus, IgA nephropathy, and drug‑resistant nephrotic syndrome.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07305116

• Finerenone for adults with IgA nephropathy

  This trial will try finerenone, a nonsteroidal mineralocorticoid receptor blocker, to lower excess urine albumin in adults with biopsy-proven IgA nephropathy who are on stable kidney-protective medications.

  Recruiting Botkin Hospital · Moscow · NCT07056595

• ADX-038 treatment for adults with complement-mediated kidney disease.

  This trial will test whether ADX-038 is safe and helps adults with complement-mediated kidney diseases such as IgA nephropathy, C3G, and IC-MPGN.

  Recruiting at 33 sites Phase 2 ADARx Pharmaceuticals, Inc. · Doral, Florida and 37 other locations · NCT06989359

• Why some cases of IgA nephropathy resist conventional and new therapies: a real-life observational look

  This project will collect real-world data from adults with biopsy-proven IgA nephropathy to see which patients keep having proteinuria or kidney decline despite modern nephroprotective measures and newer treatments.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT06926244

• Treatment of IgA Nephropathy with SC0062 Capsules

  This study is testing if SC0062 capsules can help people with IgA nephropathy and proteinuria improve their kidney function and reduce protein levels in their urine.

  Recruiting Phase 3 Biocity Biopharmaceutics Co., Ltd. · Guangzhou, Yuexiu District · NCT06819826

• Using Raman Spectroscopy to Diagnose Kidney Diseases

  This study is testing a new way to diagnose kidney diseases by analyzing urine and blood samples from patients with specific kidney conditions to see if it can help identify the diseases more accurately.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT06760845

• Avacopan plus low-dose steroid for crescentic IgA nephropathy

  This trial will test whether adding avacopan to low-dose glucocorticoids helps adults with crescentic IgA nephropathy who are at high risk of kidney progression.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Jacksonville, Florida and 1 other locations · NCT06676579

• Early targeted-release budesonide (Nefecon) for primary IgA nephropathy

  This study will try starting targeted-release budesonide early in adults with recent primary IgA nephropathy to see if it lowers protein in the urine and is safe.

  Recruiting Sichuan Provincial People's Hospital · Chengdu, Sichuan · NCT06676007

• Evaluating telitacicept for treating IgA nephropathy

  This study is testing if a new treatment called telitacicept can help people with IgA nephropathy who are at high risk of their condition getting worse.

  Recruiting Ruijin Hospital · Shanghai · NCT06654596

Related topics

Quick answers

How many IgA Nephropathy (IgAN) clinical trials are recruiting right now?

17, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in China (12 trials), United States (3 trials), Australia (1 trial), Hong Kong (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 3: 3, Early Phase 1: 2, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →